Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Xiamen Amoytop Biotech Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 22, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	16,839	34,157	29,847	21,296	15,837	11,911
Market Cap Growth	-47.30%	14.44%	40.15%	34.47%	32.96%	-14.13%
Enterprise Value	16,661	33,473	29,272	20,670	15,360	11,446
Last Close Price	45.17	82.75	71.95	50.97	37.71	28.25

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 22, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	16.12	33.12	36.06	38.34	55.18	65.73
Forward PE	13.31	25.11	29.30	33.50	28.12	28.12
PS Ratio	4.46	9.24	10.60	10.14	10.37	10.52
PB Ratio	5.78	9.90	11.69	11.35	11.25	10.26
P/TBV Ratio	6.62	11.29	12.53	12.64	12.32	11.74
P/FCF Ratio	44.54	72.18	166.48	95.23	109.98	271.61
P/OCF Ratio	25.45	46.83	69.31	41.59	43.61	50.73
PEG Ratio	0.83	0.93	0.89	-	-	-

EV Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 22, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
EV/Sales Ratio	4.42	9.06	10.39	9.84	10.06	10.11
EV/EBITDA Ratio	12.37	25.22	29.29	28.98	38.09	43.97
EV/EBIT Ratio	13.88	27.58	31.46	31.32	42.66	51.64
EV/FCF Ratio	44.10	70.73	163.28	92.42	106.67	260.99

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 22, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Debt / Equity Ratio	0.68	0.05	0.00	0.00	0.01	0.02
Debt / EBITDA Ratio	1.83	0.13	0.01	0.01	0.02	0.10
Debt / FCF Ratio	8.44	0.37	0.05	0.04	0.07	0.57
Net Debt / Equity Ratio	-0.01	-0.24	-0.26	-0.35	-0.40	-0.39
Net Debt / EBITDA Ratio	-0.04	-0.63	-0.65	-0.93	-1.39	-1.75
Net Debt / FCF Ratio	-0.16	-1.77	-3.64	-2.96	-3.90	-10.41
Asset Turnover	0.80	1.00	1.04	1.02	0.96	0.87
Inventory Turnover	0.98	0.77	0.82	0.89	1.39	1.18
Quick Ratio	6.44	3.23	3.55	2.80	3.04	4.01
Current Ratio	7.35	3.86	4.34	3.32	3.57	4.71
Return on Equity (ROE)	26.98%	34.36%	37.37%	33.83%	22.35%	16.77%
Return on Assets (ROA)	13.23%	20.43%	21.51%	19.99%	14.09%	10.59%
Return on Invested Capital (ROIC)	28.95%	47.22%	53.10%	55.56%	37.47%	29.64%
Return on Capital Employed (ROCE)	19.00%	33.10%	35.40%	33.80%	24.00%	17.80%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 22, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Earnings Yield	6.20%	3.02%	2.77%	2.61%	1.81%	1.52%
FCF Yield	2.25%	1.39%	0.60%	1.05%	0.91%	0.37%
Dividend Yield	1.46%	0.74%	0.84%	0.78%	0.55%	0.34%
Payout Ratio	23.45%	24.52%	20.15%	15.60%	14.17%	11.41%
Buyback Yield / Dilution	-0.57%	-0.38%	-0.56%	-0.29%	-0.39%	-0.18%
Total Shareholder Return	0.81%	0.36%	0.29%	0.49%	0.15%	0.17%

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error